Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic

The risk/benefit ratio of a number of palliative and (neo)adjuvant treatments should be reconsidered during the COVID-19 pandemic. We provide treatment advice as a pragmatic perspective on the risk/benefit ratio in specific clinical scenarios.

Detalles Bibliográficos
Autores principales: Gillessen, Silke, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association of Urology. Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164868/
https://www.ncbi.nlm.nih.gov/pubmed/32312544
http://dx.doi.org/10.1016/j.eururo.2020.03.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164868/
https://www.ncbi.nlm.nih.gov/pubmed/32312544
http://dx.doi.org/10.1016/j.eururo.2020.03.026

Ejemplares similares